Brief: FDA Approves New High Dose Regimen Of Spinraza® (Nusinersen) For Spinal Muscular Atrophy
30/03/2026 13:01
March 30 (Reuters) - Biogen Inc BIIB.O: FDA APPROVES NEW HIGH DOSE REGIMEN OF SPINRAZA® (NUSINERSEN) FOR SPINAL MUSCULAR ATROPHY BIOGEN - HIGH DOSE SPINRAZA TO BE AVAILABLE IN U.S. IN COMING WEEKS Source text: ID:nGNX6sRnvB Further company coverage: BIIB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout